Phaseline

Companies › Freya Biosciences ApS

Freya Biosciences ApS: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Infectious disease, Other; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FB 301
Probiotic therapeutic for bacterial vaginosis
–Phase 2Bacterial Vaginosis (BV); Vaginal DysbiosisMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07481955FB 301Phase 2Bacterial Vaginosis (BV)Infectious diseaseMar 2027
NCT07453069FB 301Phase 2Vaginal DysbiosisOtherSep 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

BioAegis Therapeutics Aligos Therapeutics BioVersys SAS Meitheal Pharmaceuticals Shanghai Yidian Pharmaceutical Technology Development

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.